Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.
Also called NCT04023344
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 210 participants
- Sponsor
- Registry
-
NCT04023344
-
- Other papers using this trial's data
- Efficacy and safety of GP40021 insulin lispro biphasic compared with Humalog Mix 25 in Type 2 diabetes mellitus patients
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT04023344. Randomized; no masking; primary purpose treatment. Start 2018-03-14 (actual); primary completion 2019-01-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Diabetes Mellitus
- Intervention (Drug)
- Humalog Mix25
- Intervention (Drug)
- Insulin Lispro Biphasic 25
- Lead sponsor
- Geropharm
Record details
- Record id
cardio:ct-nct04023344- Content hash
10d9d800520e2b9b2157ee5d518266734002ef87d6d52a41b1b114fb97a8bd9b